Navigation Links
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
Date:11/25/2008

ive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular there is no guarantee that tezampanel or NGX426 will reach additional clinical milestones, complete clinical testing, or ever be commercialized, that this amendment will build stockholder value or that this amendment will enhance the commercial value of tezampanel and NGX426. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

    Company contact:                             Investor contact:
    Paul Schneider                               Rhonda Chiger
    TorreyPines Therapeutics, Inc.               Rx Communications Group
    858-623-5665 X125                            (917) 322-2569
    pschneider@torreypinestherapeutics.com       rchiger@rxir.com

'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
2. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
3. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
6. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
7. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015  PDL BioPharma, Inc. (PDL, or the ... Company will release its second quarter 2015 financial results ... August 5, 2015, after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ... available via the webcast link on the PDL website. ...
(Date:7/28/2015)... ... July 28, 2015 , ... In terms ... in 2013; while production volume reached close to 1.84 million tonnes in the ... share of 75.5% of the region’s total aluminium hydroxide production; the country’s aluminium ...
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
Breaking Biology Technology:PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... , Human plasma and serum ... disease diagnosis. However, the wide dynamic range in protein concentration , ... for , the very low concentration of ... abundance proteins. A practical and effective strategy is to remove 99% , ...
... low-throughput disruption of a wide range of biological samples , ... , The TissueRuptor ... and cells and plant tissue. , , ... Disposable probes to help eliminate cross-contamination ...
... , ... extremely unstable upon collection of the sample, leading to changes ... applications such as real-time RT-PCR and microarray analysis,it is important ... stabilization and purification of,high-quality RNA from animal tissues, bacteria, and ...
Cached Biology Technology:Protein Depletion for Plasma and Serum Proteomic Analysis 2Protein Depletion for Plasma and Serum Proteomic Analysis 3Protein Depletion for Plasma and Serum Proteomic Analysis 4Protein Depletion for Plasma and Serum Proteomic Analysis 5Protein Depletion for Plasma and Serum Proteomic Analysis 6Protein Depletion for Plasma and Serum Proteomic Analysis 7Protein Depletion for Plasma and Serum Proteomic Analysis 8Protein Depletion for Plasma and Serum Proteomic Analysis 9Protein Depletion for Plasma and Serum Proteomic Analysis 10Protein Depletion for Plasma and Serum Proteomic Analysis 11Protein Depletion for Plasma and Serum Proteomic Analysis 12Protein Depletion for Plasma and Serum Proteomic Analysis 13Protein Depletion for Plasma and Serum Proteomic Analysis 14Protein Depletion for Plasma and Serum Proteomic Analysis 15Protein Depletion for Plasma and Serum Proteomic Analysis 16Protein Depletion for Plasma and Serum Proteomic Analysis 17Protein Depletion for Plasma and Serum Proteomic Analysis 18Protein Depletion for Plasma and Serum Proteomic Analysis 19Protein Depletion for Plasma and Serum Proteomic Analysis 20Protein Depletion for Plasma and Serum Proteomic Analysis 21Protein Depletion for Plasma and Serum Proteomic Analysis 22Protein Depletion for Plasma and Serum Proteomic Analysis 23Protein Depletion for Plasma and Serum Proteomic Analysis 24Protein Depletion for Plasma and Serum Proteomic Analysis 25Protein Depletion for Plasma and Serum Proteomic Analysis 26Protein Depletion for Plasma and Serum Proteomic Analysis 27Protein Depletion for Plasma and Serum Proteomic Analysis 28Protein Depletion for Plasma and Serum Proteomic Analysis 29Protein Depletion for Plasma and Serum Proteomic Analysis 30Protein Depletion for Plasma and Serum Proteomic Analysis 31Protein Depletion for Plasma and Serum Proteomic Analysis 32TissueRuptor System 2TissueRuptor System 3Successful stabilization of gene expression profiles 2Successful stabilization of gene expression profiles 3
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... carried a gene that increases your risk for Alzheimer,s disease? And ... damage not when you,re old but when you,re young? ... strong genetic component to the development of late-onset Alzheimer,s. In 1993, ... a quarter of us that triples the risk for getting ...
... ARLINGTON, VA (May 3, 2011) Cancer studies from ... unveiled at the American Association of Pharmaceutical Scientists, (AAPS) ... May 16 -Wednesday, May 18 at the Hilton San ... Oral Vaccine for Cervical Cancer Cervical cancer ...
... overcome their evolutionary legacies to become much better at ... of energy that can power vehicles in the near ... solar scientists has found. A U.S. Department of ... 18 scientists to compare the efficiency of plants and ...
Cached Biology News:Alzheimer's risk gene disrupts brain's wiring 50 years before disease hits 2Alzheimer's risk gene disrupts brain's wiring 50 years before disease hits 3AAPS national biotechnology conference to highlight breakthrough cancer treatments 2NREL's multi-junction solar cells teach scientists how to turn plants into powerhouses 2NREL's multi-junction solar cells teach scientists how to turn plants into powerhouses 3
Request Info...
Spaced cover glasses to promote effective hybridization...
... Detection Platform combines robust chemistry with ... sensitive, specific, and cost-effective detection method ... Platform offers exceptional performance with specificity ... high signal/background ratio, and an expanded ...
Request Info...
Biology Products: